Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Raltegravir efficacy maintained through 48 weeks in BENCHMRK studies

Feb. 19, 2008

VICTOR-E1 data show sustained viral suppression with vicriviroc in HIV patients

Feb. 19, 2008

GeoVax Clade B DNA/MVA HIV/AIDS vaccine to proceed to phase II

Feb. 19, 2008

Improved body composition seen with tesamorelin in HIV-associated lipohypertrophy

Feb. 18, 2008

Activity of RDEA-806 less affected by human serum proteins than other NNRTIs

Feb. 18, 2008

VRX-496 affects HIV replication in phase II trial

Feb. 18, 2008

Robust immune responses with multiclade HIV-1 DNA plasmid vaccine in phase I/II studies

Feb. 15, 2008

Results from Merck & Co. HIV vaccine reported at the CROI meeting

Feb. 15, 2008

PF-232798 profiled at the CROI meeting

Feb. 14, 2008

Promising anti-HIV profile for novel NNRTIs developed at Ardea

Feb. 14, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 3, 2026